The relationship between the urokinase-type plasminogen activator gene Pro141Leu polymorphism and patients with prostate cancer
Revista da Associação Médica Brasileira · 2025
DOI: 10.1590/1806-9282.20250097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista da Associação Médica Brasileira, 2025. Verfasst von Cemil Gülüm und 3 weiteren Autor:innen. Beteiligte Einrichtung: Mersin University, Faculty of Science, Department of Chemistry - Mersin, Turkey. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Urokinase-Type Plasminogen Activator, Polymorphism, Genetic. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University Scientific Research Projects Unit with the project.
Abstract (Originalsprache)
OBJECTIVE: Although many genes associated with prostate cancer have been identified, there are still many cases of prostate cancer whose genetics have not been identified. The urokinase-type plasminogen activator gene is thought to play a key role in cancer invasion and metastasis. The Pro141Leu polymorphism may be involved in the development of prostate cancer, although genetic evidence is lacking. METHODS: We used the real time polymerase chain reaction based TaqMan assay to investigate whether the urokinase-type plasminogen activator gene Pro141Leu polymorphism is associated with prostate cancer patients and healthy controls. urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and prostate-specific antigen antigens were assayed by the enzyme-linked immunosorbent assay method. RESULTS: We found no significant differences between the cancer and control populations in terms of genotype distribution (CC, CT, and TT). Furthermore, we found no association between the urokinase-type plasminogen activator gene Pro141Leu polymorphism and cancer risk in prostate cancer patients. CONCLUSION: This is the first study to investigate the association between the rs2227564 polymorphism and prostate cancer. Although the urokinase-type plasminogen activator gene Pro141Leu polymorphism has been reported to be a risk factor for some cancers, our findings suggest that the urokinase-type plasminogen activator gene Pro141Leu polymorphism is not an important genetic risk factor for prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mersin University, Faculty of Science, Department of Chemistry - Mersin, Turkey.
- Mersin University, Faculty of Medicine, Department of Biochemistry - Mersin, Turkey.
- Mersin University, Faculty of Medicine, Department of Urology - Mersin, Turkey.
Förderung
- University Scientific Research Projects Unit with the project
Zitieren
APA
Gülüm, C., Eroğlu, P., Tanrıverdi, R., & Bozlu, M. (2025). The relationship between the urokinase-type plasminogen activator gene Pro141Leu polymorphism and patients with prostate cancer. Revista da Associação Médica Brasileira. https://doi.org/10.1590/1806-9282.20250097
Vancouver
Gülüm C, Eroğlu P, Tanrıverdi R, Bozlu M. The relationship between the urokinase-type plasminogen activator gene Pro141Leu polymorphism and patients with prostate cancer. Revista da Associação Médica Brasileira. 2025. doi:10.1590/1806-9282.20250097
BibTeX
@article{Glm2025,
author = {Gülüm, Cemil and Eroğlu, Pelin and Tanrıverdi, Rojda and Bozlu, Murat},
title = {The relationship between the urokinase-type plasminogen activator gene Pro141Leu polymorphism and patients with prostate cancer},
journal = {Revista da Associação Médica Brasileira},
year = {2025},
doi = {10.1590/1806-9282.20250097}
}
EUVIMED